These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26381259)

  • 21. Germline CDKN2A mutations in childhood melanoma.
    Whiteman DC; Milligan A; Welch J; Green AC; Hayward NK
    J Natl Cancer Inst; 1997 Oct; 89(19):1460. PubMed ID: 9326917
    [No Abstract]   [Full Text] [Related]  

  • 22. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
    Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
    J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
    Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
    J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial pancreatic cancer.
    Klein AP; Hruban RH; Brune KA; Petersen GM; Goggins M
    Cancer J; 2001; 7(4):266-73. PubMed ID: 11561603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reply to: "The absence of multiple atypical nevi in germline CDKN2A mutations".
    Soura E; Stratigos AJ; Tsao H
    J Am Acad Dermatol; 2016 Oct; 75(4):e159. PubMed ID: 27646764
    [No Abstract]   [Full Text] [Related]  

  • 27. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial melanoma and pancreatic cancer.
    Bergman W; Gruis N
    N Engl J Med; 1996 Feb; 334(7):471-2. PubMed ID: 8552160
    [No Abstract]   [Full Text] [Related]  

  • 29. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
    Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
    Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
    de Torre C; Martínez-Escribano J
    Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group.
    Ciotti P; Strigini P; Bianchi-Scarrà G
    N Engl J Med; 1996 Feb; 334(7):469-70; author reply 471-2. PubMed ID: 8552158
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
    Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
    J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
    Horn IP; Marks DL; Koenig AN; Hogenson TL; Almada LL; Goldstein LE; Romecin Duran PA; Vera R; Vrabel AM; Cui G; Rabe KG; Bamlet WR; Mer G; Sicotte H; Zhang C; Li H; Petersen GM; Fernandez-Zapico ME
    J Biol Chem; 2021; 296():100634. PubMed ID: 33823155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma.
    Bullock GJ; Green JL; Baron PL
    Am J Surg; 1999 Jan; 177(1):15-8. PubMed ID: 10037301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
    Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
    Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
    Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
    J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiological features and prognostic parameters of multiple primary melanomas in CDKN2A-mutations patients.
    De Giorgi V; Savarese I; D'Errico A; Gori A; Papi F; Colombino M; Sini MC; Grazzini M; Stanganelli I; Rossari S; Covarelli P; Massi D; Palmieri G
    Pigment Cell Melanoma Res; 2015 Nov; 28(6):747-51. PubMed ID: 26223839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.